On April 17, 2026 OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, reported that the AACR (Free AACR Whitepaper) 2026 abstract reporting interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durvalumab) and platinum-based chemotherapy in patients with resectable early stage non-small cell lung cancer (NSCLC) has been published.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Summary of the abstract: Perioperative PD-(L)1 inhibitors combined with chemotherapy are now standard for resectable early-stage NSCLC, but further improvements in pathological complete response (pCR) and survival are still needed. IPH5201, an anti-CD39 antibody, aims to enhance antitumor immunity by reducing immunosuppressive adenosine and increasing ATP levels. In the Phase 2 MATISSE study, IPH5201 was added to durvalumab and chemotherapy in patients with stage II–IIIA NSCLC. Among 40 patients, the treatment showed a favorable safety profile and achieved a pCR rate of 27.5% (all), rising to 35.7% in PD-L1 ≥1% and 50% in PD-L1 ≥50% patients, comparing favorably with the 17.2%, 21.2% and 27.5% reported for durvalumab + chemo in the AEGEAN study (Heymach, 2023). Biomarker analyses confirmed CD39 target engagement and suggested a link between CD39+ tumor cell density and response. These results compare favorably to prior standards and support the continuation of the study with the recruitment of PD-L1≥1% pts.

Presentation details:

Session CTPL04 – Advances in Immunotherapy
CT231 – Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC.

Session Date/Time: April 21, 2026, 10:45 AM – 11:00 AM Hall H – Ground Level – Convention Center

Presenter: Pr. Fabrice Barlesi, CEO of Institut Gustave Roussy

About IPH5201 antibody
IPH5201 is a humanized CD39 blocking antibody codeveloped by Innate Pharma and AstraZeneca (AZ).
OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody (IPH5201) has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody).

About NCT05742607 clinical trial
MATISSE is a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201 in combination with durvalumab (anti-PD-L1, AZ) and chemotherapy in treatment-naïve patients with resectable early-stage non-small cell lung cancer (NSCLC). The primary objectives of the study are to assess antitumor activity of neoadjuvant treatment based on pathological complete response (pCR) and safety. More information on the Phase 2 clinical trial is accessible online.

(Press release, OREGA BIOTECH, APR 17, 2026, View Source [SID1234664546])